Fig. 2From: Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancerKaplan-Meier analysis of (a) overall survival and (b) progression-free survival for three subgroups (the poor, intermediate, and good prognostic groups) according to prognostic index using Glasgow prognostic score and carcinoembryonic antigen level. CI confidence interval. *p < 0.05, **p < 0.01Back to article page